Press Releases

Sign up for Email Alerts Press Release RSS

01/24/2019
Bristol-Myers Squibb Announces Time Change for Q4 Earnings Results Conference Call
Term:Corporate/Financial News
Language:English
01/24/2019
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
Term:Corporate/Financial News
Language:English
01/14/2019
European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Term:Corporate/Financial News
Language:English
01/05/2019
Bristol-Myers Squibb to Participate in the 37th Annual J.P. Morgan Healthcare Conference
Term:Corporate/Financial News
Language:English
01/03/2019
Bristol-Myers Squibb Provides 2019 EPS Guidance
Term:Corporate/Financial News
Language:English
01/03/2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Term:Corporate/Financial News
Language:English
01/02/2019
Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Term:Corporate/Financial News
Language:English
12/19/2018
Bristol-Myers Squibb Announces Offer from Taisho Pharmaceutical Holdings Co., Ltd to Purchase UPSA
Term:Bristol-Myers
Language:English
12/17/2018
Bristol-Myers Squibb and Boston Medical Center Announce Research Collaboration to Investigate Markers of Immuno-Oncology Response and Resistance
Term:Corporate/Financial News
Language:English
12/17/2018
Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3’s RNA Splicing Platform
Term:R&D News
Language:English

Business Wire NewsHQ^sm